AstraZeneca Pharma India Limited (NSE:ASTRAZEN)
India
· Delayed Price · Currency is INR | Market Cap | 212.35B |
| Revenue (ttm) | 16.19B |
| Net Income (ttm) | 969.70M |
| Shares Out | n/a |
| EPS (ttm) | 38.78 |
| PE Ratio | 218.98 |
| Forward PE | n/a |
| Dividend | 24.00 (0.29%) |
| Ex-Dividend Date | Jul 5, 2024 |
| Volume | 30,394 |
| Average Volume | 85,987 |
| Open | 8,510.00 |
| Previous Close | 8,494.65 |
| Day's Range | 8,430.30 - 8,759.00 |
| 52-Week Range | 4,800.15 - 9,059.05 |
| Beta | 0.33 |
| RSI | 75.08 |
| Earnings Date | May 29, 2025 |
About AstraZeneca Pharma India
AstraZeneca Pharma India Limited, a biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease, renal, and metabolism medicines under the CRESTOR, Forxiga, BRILINTA, Xigduo, and Seloken XL brand names; oncology medicines under the TAGRISSO, CALQUENCE, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra bran... [Read more]
Financial Performance
In 2023, AstraZeneca Pharma India's revenue was 12.96 billion, an increase of 29.17% compared to the previous year's 10.03 billion. Earnings were 1.62 billion, an increase of 62.66%.
Financial StatementsNews
AstraZeneca Pharma gets approval for additional indication of Durvalumab (Imfinzi) in India
AstraZeneca Pharma India Limited has received approval from the Central Drugs Standard Control Organisation (CDSCO), India, to import, sell, and distribute Durvalumab (Imfinzi) solution for infusion i...
AstraZeneca receives approval to import Lokelma for hyperkalaemia treatment in India
AstraZeneca Pharma India Limited has received regulatory approval from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India, to import a...
AstraZeneca receives approval to import and distribute Eculizumab
AstraZeneca Pharma India Limited has announced that it has received regulatory approval to import and distribute Eculizumab concentrate for solution (300 mg, 10mg/ml) under the brand name SOLIRIS. Thi...
AstraZeneca Pharma India gets sale approval for additional indication of Olaparib film-coated tablets
AstraZeneca Pharma India Limited has received significant regulatory approval under Form CT-20 from the Central Drugs Standard Control Organisation (CDSCO). This allows the company to import, sell and...
Astrazeneca Pharma India shares surge 3% on Breztri Aerosphere launch announcement
AstraZeneca Pharma India Ltd saw its shares rise by 3% after announcing the launch of Breztri Aerosphere in January 2025. The company has received approval from the Drugs Controller General of India (...
AstraZeneca Pharma India to launch Breztri Aerosphere in January 2025
AstraZeneca Pharma India Limited has announced the upcoming launch of Breztri Aerosphere in January 2025. This innovative inhalation therapy combines Budesonide Ph. Eur 160 mcg, Glycopyrronium Ph. Eur...
AstraZeneca Pharma India shares surge over 8% amid focus on cancer projects and clinical trials
Shares of AstraZeneca Pharma India Ltd. witnessed a sharp rise of 8.26% on October 7, trading at ₹8,051. The stock opened at ₹7,440, surged to an intraday high of ₹8,129.95, and has been moving positi...
AstraZeneca Pharma surges over 7%, hits 52-week high during early trades
AstraZeneca Pharma India Ltd witnessed a significant surge in its stock price, rising over 7% to ₹7,697 as of 10:11 AM today. The stock opened at ₹7,150, reached a high of ₹7,743, and recorded a low o...
AstraZeneca gets nod to launch cancer drug
AstraZeneca Pharma India has received approval from the Central Drugs Standard Control Organisation to import Durvalumab for sale and distribution. The drug, combined with chemotherapy, treats resecta...